Understanding underreporting of ADR in the Philippines

08 June 2022
About the research

Collaboration:

Special Programme for Research and Training in Tropical Diseases (TDR)

Title:
“Understanding underreporting of adverse drug reactions in the Philippines”

Year proposed: 2019
Year granted: 2021
Grant: USD 50,000

PI: Mark Ryann A. Lirasan, RPh
Head, Pharmacovigilance
Food and Drug Administration
Philippines

Co-PI: Mark Harvey Adamson, RPh
Dean, School of Pharmacy
Philippine Women’s University
Objectives

“Understanding underreporting of adverse drug reactions in the Philippines”

1. Assess the knowledge, prevailing attitudes and current practices on ADR reporting among healthcare professionals at the public health facility level and within public health programs to understand country-specific factors that may be contributing to ADR reporting;

2. Assess the effectiveness of the eReporting module for VigiFlow among healthcare professionals

3. Assess the usability of the eReporting module for VigiFlow among healthcare providers
Study Design

“Understanding underreporting of adverse drug reactions in the Philippines”

K A P

quantitative

FGD

qualitative

eReporting

MODULE FOR VIGIFLOW®
“Understanding underreporting of adverse drug reactions in the Philippines”
Research

“Understanding underreporting of adverse drug reactions in the Philippines”

Have you ever reported what you suspected to be an adverse drug reaction (ADR) associated with a medication?

- Yes: 78.6%
- No: 21.4%
“Understanding underreporting of adverse drug reactions in the Philippines”

If you suspected an adverse event associated with a medication, would you know how to report it?

- Yes: 68.6%
- No: 31.4%
Research

“Understanding underreporting of adverse drug reactions in the Philippines”

Which of the following is (are) available reporting options (in your workplace) for ADR reporting?

- Paper-based reporting: 58.5%
- Online Reporting (eReporting): 43.1%
- Telephone call to the National Pharmacovigilance Center: 13.4%
- No idea: 20.2%
“Understanding underreporting of adverse drug reactions in the Philippines”

If you are going to report a suspected ADR, which of the following methods do you prefer

- Fax: 2%
- Online (Website): 77.7%
- Online (thru Mobile App): 54.8%
- Mail-in form: 21.3%
- Call NPV Center to Report: 20.3%
- Text NPV Center to Report: 16%
“Understanding underreporting of adverse drug reactions in the Philippines”

**eReporting**

**MODULE FOR VIGIFLOW®**

How did you access the e-Reporting link?

- I didn't access the e-Reporting Link and wish to withdraw on this survey: 65.8%
- via Desktop/Laptop Browser: 28.1%
- via Mobile Phone Browser: 6.1%

On the screen that contains 'Send Report', what was the last word appearing on the UPPER part of screen.

*If you choose the incorrect answer, you are directed to the same link so that you can try again.*
1. I think I would like to use this eReporting System frequently.

641 responses

<table>
<thead>
<tr>
<th>Score</th>
<th>Count</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4</td>
<td>0.6%</td>
</tr>
<tr>
<td>2</td>
<td>5</td>
<td>0.8%</td>
</tr>
<tr>
<td>3</td>
<td>63</td>
<td>9.8%</td>
</tr>
<tr>
<td>4</td>
<td>186</td>
<td>29%</td>
</tr>
<tr>
<td>5</td>
<td>383</td>
<td>59.8%</td>
</tr>
</tbody>
</table>
“Understanding underreporting of adverse drug reactions in the Philippines”

2. I found the eReporting System unnecessarily complex.

641 responses

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>125 (19.5%)</td>
<td>136 (21.2%)</td>
<td>150 (23.4%)</td>
<td>121 (18.9%)</td>
<td>109 (17%)</td>
</tr>
</tbody>
</table>

This is a standard 10-item questionnaire that measures the overall usability of FDA eReporting System. Please select an answer that best expresses how you feel about each statement after using the eReporting System.

1 - Strongly Disagree | 2 - Disagree | 3 - Neutral | 4 - Agree | 5 - Strongly Agree

FDA eReporting (System Usability Survey)
“Understanding underreporting of adverse drug reactions in the Philippines”

3. I thought the eReporting System was easy to use.

641 responses

<table>
<thead>
<tr>
<th>Rating</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7</td>
<td>1.1%</td>
</tr>
<tr>
<td>2</td>
<td>14</td>
<td>2.2%</td>
</tr>
<tr>
<td>3</td>
<td>133</td>
<td>20.7%</td>
</tr>
<tr>
<td>4</td>
<td>224</td>
<td>34.9%</td>
</tr>
<tr>
<td>5</td>
<td>263</td>
<td>41%</td>
</tr>
</tbody>
</table>
"Understanding underreporting of adverse drug reactions in the Philippines"

4. I think that I would need the support of a technical person to be able to use this eReporting System.
641 responses
"Understanding underreporting of adverse drug reactions in the Philippines"

5. I found the various functions in this eReporting System were well integrated.

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (0.2%)</td>
<td>7 (1.1%)</td>
<td>81 (12.6%)</td>
<td>247 (38.5%)</td>
<td>305 (47.6%)</td>
</tr>
</tbody>
</table>

641 responses
“Understanding underreporting of adverse drug reactions in the Philippines”

6. I thought there was too much inconsistency in this eReporting System.
641 responses

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>131 (20.4%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>163 (25.4%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>162 (25.3%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>83 (12.9%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>102 (15.9%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
7. I would imagine that most people would learn to use this eReporting System very quickly

641 responses

- 7 (1.1%)
- 14 (2.2%)
- 108 (16.8%)
- 204 (31.8%)
- 308 (48%)
“Understanding underreporting of adverse drug reactions in the Philippines”

8. I found the eReporting System very awkward to use.
641 responses
“Understanding underreporting of adverse drug reactions in the Philippines”

9. I felt very confident using the eReporting System.
641 responses

![Bar chart showing confidence levels](chart.png)
Research

“Understanding underreporting of adverse drug reactions in the Philippines”

10. I needed to learn a lot of things before I could get going with this eReporting System.

641 responses

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>64 (10%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>72 (11.2%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>135 (21.1%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>172 (26.8%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>198 (30.9%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
“Understanding underreporting of adverse drug reactions in the Philippines”

Ongoing: Focused Group Discussions

Expected end of research: before end of 2022
Publication: 2022-2023
Future directions...

1. Identify Gaps
2. Create and implement interventions
3. Evaluate intervention
4. Propose further development
THANK YOU!

www.fda.gov.ph

info@fda.gov.ph